|
Recruiting
|
NCT05081024 -
Establishing a ctDNA Biomarker to Improve Organ Preserving Strategies in Patients With Rectal Cancer
|
|
|
Recruiting
|
NCT04599140 -
SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial
|
Phase 1/Phase 2 |
|
Active, not recruiting
|
NCT04362839 -
Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer
|
Phase 1 |
|
Recruiting
|
NCT02107105 -
Evaluation of Quality of Life and Utilities Following Surgical Treatment of Stage I-IV Rectal Cancer
|
|
|
Terminated
|
NCT04406857 -
Testing the Addition of a Radiation Sensitizing Drug, IPdR, to the Usual Chemotherapy Treatment (Capecitabine) During Radiation Therapy for Rectal Cancer
|
Phase 1 |
|
Recruiting
|
NCT03594630 -
Active Surveillance and Chemotherapy Before Surgery in Treating Participants With Stage II-III Rectal Cancer
|
Early Phase 1 |
|
Active, not recruiting
|
NCT03516942 -
Financial Burden Assessment in Patients With Stage I-III Colon or Rectal Cancer Undergoing Treatment
|
|
|
Terminated
|
NCT03592641 -
Savolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal Cancer
|
Phase 2 |
|
Recruiting
|
NCT05308446 -
Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation
|
Phase 2 |
|
Recruiting
|
NCT05722288 -
Time-Restricted Eating Versus Nutritional Counseling for the Reduction of Radiation or Chemoradiation Tx Side Effects in Patients With Prostate, Cervical, or Rectal Cancers
|
Phase 2 |
|
Suspended
|
NCT04751370 -
Testing Nivolumab and Ipilimumab With Short-Course Radiation in Locally Advanced Rectal Cancer
|
Phase 2 |
|
Recruiting
|
NCT04703101 -
Short Course Radiation Therapy and Combination Chemotherapy for the Treatment of Stage II-III Rectal Cancer
|
Phase 1 |
|
Recruiting
|
NCT05610163 -
Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation
|
Phase 2 |
|
Active, not recruiting
|
NCT04109924 -
TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study
|
Phase 2 |
|
Active, not recruiting
|
NCT04616183 -
LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer
|
Phase 1/Phase 2 |
|
Recruiting
|
NCT04104139 -
TAS-102 With Concurrent Radiation for the Treatment of Untreated Resectable Stage II-III Rectal Cancer
|
Phase 1 |
|
Recruiting
|
NCT04929028 -
Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer
|
Phase 2 |
|
Recruiting
|
NCT05245786 -
An Investigational Scan (64Cu-Labeled M5A Antibody) in Combination With SOC Chemotherapy and Radiotherapy in Locally Advanced Rectal Cancer
|
Early Phase 1 |
|
Active, not recruiting
|
NCT03992456 -
Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer
|
Phase 2 |
|
Terminated
|
NCT03765736 -
Genetic Testing in Screening Patients With Metastatic or Unresectable Colon or Rectal Cancer for a COLOMATE Trial
|
|